[Diagnostic kits in parasitology: which controls?].

Area of Science:

• Parasitology and Tropical Diseases
• Diagnostic Development and Validation
• Biotechnology and Public Health

Context:

• Development of novel diagnostic tools for neglected parasitic diseases is hampered by insufficient research funding in public and private sectors.
• Industry investment in In Vitro Diagnostic (IVD) tests for these diseases is limited due to perceived small market sizes.
• The Foundation for Innovative New Diagnostics (FIND) was established to bridge this gap by leveraging biotechnology for affordable diagnostics.

Purpose:

• To highlight the critical need for standardized, validated diagnostic tests for parasitic diseases, particularly in resource-limited settings.
• To emphasize the importance of pre-clinical and clinical evaluation phases, including analytical studies and population-based assessments.
• To underscore the role of international standards and regulatory bodies in ensuring the quality and reliability of diagnostic devices.

Summary:

• International reference standards are largely unavailable for parasitic diseases, except for Toxoplasma antibodies, hindering accurate diagnostic test calibration.
• A proposed four-phase validation process (pre-clinical, proof of principle, intended use evaluation, cost-effectiveness) is crucial for diagnostic development.
• Regulatory agencies like the European Community and the US FDA provide frameworks for IVD approval and surveillance, though resource limitations in developing countries pose challenges.

Impact:

• Establishing international reference standards and robust validation frameworks is essential for improving diagnostic accuracy and accessibility for neglected tropical diseases.
• Enhanced regulatory oversight and standardization can foster greater industry investment and accelerate the availability of reliable diagnostics.
• Successful implementation of these measures will ultimately improve patient outcomes and disease control efforts globally.